BioTime, Inc. (NYSEMKT:BTX) belongs to Healthcare sector. Its weekly performance is -6.01%. On last trading day company shares ended up $3.44. BioTime, Inc. (NYSEMKT:BTX) distance from 50-day simple moving average (SMA50) is -21.43%. On June 30, 2015, BioTime, Inc. (NYSEMKT:BTX) subsidiary OncoCyte Corporation (“OncoCyte”) entered into an Agreement with two of its shareholders (the “Investors”) who purchased shares of OncoCyte common stock in a rights offering that was completed on May 8, 2015. Under the Agreement, the Investors have agreed that if on or before June 30, 2016 OncoCyte conducts another rights offering to its shareholders at a pre-offer valuation of at least $40,000,000, the Investors will purchase shares in that offering with an aggregate purchase price equal to the lesser of (a) a percentage of total amount of capital which OncoCyte then seeks to raise in the rights offer and in any concurrent offering to third parties equal to the Investors’ aggregate pro rata share of the outstanding OncoCyte common stock on the record date for the rights offering, determined on a fully diluted basis, and (b) $3,000,000.00, or such lesser amount requested by OncoCyte.
AppFolio, Inc. (NASDAQ:APPF) shares increased 11.97% in last trading session and ended the day at $16.56. APPF Gross Margin is 53.60% and its return on assets is -71.70%. On 8 July, AppFolio, Inc. (NASDAQ:APPF) announced that, in connection with its initial public offering of Class A common stock, which closed on June 30, 2015, the underwriters have exercised their over-allotment option in full to purchase an additional 930,000 shares of Class A common stock from the Company at a price of $12.00 per share.
On 13 July, (NASDAQ:PETX) shares increased 5.89% and was closed at $16.55. Aratana Therapeutics, Inc. (NASDAQ:PETX) year to date (YTD) performance is -7.13%. On 26 June, Aratana Therapeutics, Inc. (NASDAQ:PETX), announced positive results from its pivotal field effectiveness study of capromorelin (AT-002), the company’s innovative therapeutic for appetite stimulation in dogs.
Tessera Technologies Inc. (NASDAQ:TSRA) ended the last trading day at $36.27. Company weekly volatility is calculated as 2.96% and price to cash ratio as 4.38. Tessera Technologies Inc. (NASDAQ:TSRA) showed a weekly performance of -3.92%. Zacks cut shares of Tessera Technologies (NASDAQ:TSRA) from a buy rating to a hold rating in a research note issued to investors on Tuesday, Marketbeat.com reports.
The Timken Company (NYSE:TKR) shares increased 1.46% in last trading session and ended the day at $35.34. TKR Gross Margin is 28.80% and its return on assets is 1.20%. The Timken Company (NYSE:TKR) quarterly performance is -14.52%. The Timken Company (NYSE: TKR;) will release its 2015 second-quarter financial results on Thursday, July 30, prior to the opening of the New York Stock Exchange.